Opzelura (Ruxolitinib)

Ruxolitinib, the active ingredient in Opzelura, is a Janus kinase (JAK) inhibitor presented as a 1.5% w/w cream for topical use. It treats atopic dermatitis in patients who need a non‑systemic option or have not responded adequately to conventional therapies.

GNH USA supplies Opzelura as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Opzelura (ruxolitinib) is a topical Janus kinase inhibitor indicated for inflammatory skin conditions.

Adult atopic dermatitis: improves skin lesions and reduces itch in adults with moderate to severe disease. Pediatric atopic dermatitis: provides similar benefits in children aged 12 years and older with moderate to severe disease. Inadequate response to topical corticosteroids: offers an alternative topical therapy to control inflammation when steroids are insufficient.

Common Side Effects: - Application site irritation: redness, burning, or stinging at the site of cream application. - Pruritus: transient itching that may occur shortly after use. - Dryness or scaling of the treated skin. - Erythema: mild redness of the skin. - Folliculitis: inflammation of hair follicles. - Contact dermatitis: allergic skin reaction to the formulation.

Serious or Rare Side Effects: - Skin infection: bacterial, viral, or fungal infection of the treated area. - Severe allergic reaction: angioedema or anaphylaxis requiring immediate medical attention. - Disseminated herpes simplex or zoster infections. - Malignancy: rare reports of skin cancers with prolonged immunosuppression. - Systemic immunosuppression: potential for increased susceptibility to opportunistic infections.

Before using Opzelura, consider the following precautions: - Avoid use on infected or broken skin: may worsen infection. - Do not apply to areas with active eczema herpeticum: risk of viral spread. - Monitor for signs of infection: redness, swelling, or pus formation. - Limit application to prescribed body surface area: excessive use can increase systemic exposure. - Pregnancy and lactation: safety unknown; discuss risks with a healthcare professional. - Store at room temperature below 25°C: keep in the original container, protect from moisture and light.

Opzelura may interact with other agents that affect immune function.

Major Interactions (Avoid): - Concomitant systemic immunosuppressants (e.g., methotrexate, cyclosporine): additive risk of infection. - Use with other topical JAK inhibitors: excessive local immunosuppression.

Moderate Interactions (Monitor Closely): - Topical corticosteroids: may increase local immunosuppressive effect. - Antifungal creams (e.g., azoles): potential reduction in antifungal efficacy. - Live vaccines: may diminish vaccine response; consider timing of vaccination.